DE956291T1 - Galanin galr3 rezeptor-kodierende dna und anwendungen - Google Patents
Galanin galr3 rezeptor-kodierende dna und anwendungenInfo
- Publication number
- DE956291T1 DE956291T1 DE0956291T DE97910850T DE956291T1 DE 956291 T1 DE956291 T1 DE 956291T1 DE 0956291 T DE0956291 T DE 0956291T DE 97910850 T DE97910850 T DE 97910850T DE 956291 T1 DE956291 T1 DE 956291T1
- Authority
- DE
- Germany
- Prior art keywords
- galr3 receptor
- receptor
- cell
- galr3
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 101001072777 Homo sapiens Galanin receptor type 3 Proteins 0.000 title claims 246
- 102100036588 Galanin receptor type 3 Human genes 0.000 title claims 237
- 101800002068 Galanin Proteins 0.000 title claims 2
- 102000019432 Galanin Human genes 0.000 title claims 2
- SLZIZIJTGAYEKK-CIJSCKBQSA-N molport-023-220-247 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)CN)[C@@H](C)O)C1=CNC=N1 SLZIZIJTGAYEKK-CIJSCKBQSA-N 0.000 title claims 2
- 150000001875 compounds Chemical class 0.000 claims 164
- 238000000034 method Methods 0.000 claims 150
- 210000004027 cell Anatomy 0.000 claims 122
- 150000007523 nucleic acids Chemical class 0.000 claims 64
- 108020004707 nucleic acids Proteins 0.000 claims 61
- 102000039446 nucleic acids Human genes 0.000 claims 61
- 150000001413 amino acids Chemical group 0.000 claims 50
- 230000027455 binding Effects 0.000 claims 40
- 108020004414 DNA Proteins 0.000 claims 28
- 239000005557 antagonist Substances 0.000 claims 22
- 230000004913 activation Effects 0.000 claims 21
- 239000008194 pharmaceutical composition Substances 0.000 claims 20
- 239000013612 plasmid Substances 0.000 claims 20
- 230000000694 effects Effects 0.000 claims 18
- 102000005962 receptors Human genes 0.000 claims 17
- 108020003175 receptors Proteins 0.000 claims 17
- 210000004962 mammalian cell Anatomy 0.000 claims 16
- 102000011392 Galanin receptor Human genes 0.000 claims 15
- 108050001605 Galanin receptor Proteins 0.000 claims 15
- 229940044551 receptor antagonist Drugs 0.000 claims 15
- 239000002464 receptor antagonist Substances 0.000 claims 15
- 230000005856 abnormality Effects 0.000 claims 14
- 239000000018 receptor agonist Substances 0.000 claims 13
- 229940044601 receptor agonist Drugs 0.000 claims 13
- 230000009261 transgenic effect Effects 0.000 claims 13
- 239000000556 agonist Substances 0.000 claims 12
- 239000003937 drug carrier Substances 0.000 claims 12
- 241000238631 Hexapoda Species 0.000 claims 11
- 239000012528 membrane Substances 0.000 claims 11
- 108020004711 Nucleic Acid Probes Proteins 0.000 claims 10
- 210000002569 neuron Anatomy 0.000 claims 10
- 239000002853 nucleic acid probe Substances 0.000 claims 10
- 241001465754 Metazoa Species 0.000 claims 9
- 102000048410 human GALR3 Human genes 0.000 claims 9
- 230000004044 response Effects 0.000 claims 9
- 239000000284 extract Substances 0.000 claims 8
- 235000012631 food intake Nutrition 0.000 claims 8
- 108020004999 messenger RNA Proteins 0.000 claims 8
- 125000003729 nucleotide group Chemical group 0.000 claims 8
- 210000003734 kidney Anatomy 0.000 claims 7
- 108091034117 Oligonucleotide Proteins 0.000 claims 6
- 210000004978 chinese hamster ovary cell Anatomy 0.000 claims 6
- 230000000295 complement effect Effects 0.000 claims 6
- 230000037406 food intake Effects 0.000 claims 6
- 230000001537 neural effect Effects 0.000 claims 6
- 239000002773 nucleotide Substances 0.000 claims 6
- 230000001105 regulatory effect Effects 0.000 claims 6
- 102100028447 Galanin receptor type 1 Human genes 0.000 claims 5
- 101001061554 Homo sapiens Galanin receptor type 1 Proteins 0.000 claims 5
- 101100447617 Rattus norvegicus Galr3 gene Proteins 0.000 claims 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 5
- 208000035475 disorder Diseases 0.000 claims 5
- 230000001965 increasing effect Effects 0.000 claims 5
- 239000000523 sample Substances 0.000 claims 5
- 238000012216 screening Methods 0.000 claims 5
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims 4
- 102100036584 Galanin receptor type 2 Human genes 0.000 claims 4
- 101001072780 Homo sapiens Galanin receptor type 2 Proteins 0.000 claims 4
- 230000008859 change Effects 0.000 claims 4
- 238000002360 preparation method Methods 0.000 claims 4
- 230000002829 reductive effect Effects 0.000 claims 4
- 230000009870 specific binding Effects 0.000 claims 4
- 102100033063 G protein-activated inward rectifier potassium channel 1 Human genes 0.000 claims 3
- 102100021237 G protein-activated inward rectifier potassium channel 4 Human genes 0.000 claims 3
- 101000944266 Homo sapiens G protein-activated inward rectifier potassium channel 1 Proteins 0.000 claims 3
- 101000614712 Homo sapiens G protein-activated inward rectifier potassium channel 4 Proteins 0.000 claims 3
- 101000860415 Homo sapiens Galanin peptides Proteins 0.000 claims 3
- 102100029549 Neuropeptide Y receptor type 5 Human genes 0.000 claims 3
- 101710198055 Neuropeptide Y receptor type 5 Proteins 0.000 claims 3
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 3
- 239000000074 antisense oligonucleotide Substances 0.000 claims 3
- 238000012230 antisense oligonucleotides Methods 0.000 claims 3
- 239000012634 fragment Substances 0.000 claims 3
- 230000001939 inductive effect Effects 0.000 claims 3
- 230000003834 intracellular effect Effects 0.000 claims 3
- 210000003292 kidney cell Anatomy 0.000 claims 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 2
- 108700028369 Alleles Proteins 0.000 claims 2
- 101150103804 GAL3 gene Proteins 0.000 claims 2
- 229940121970 Galanin receptor antagonist Drugs 0.000 claims 2
- 102100039558 Galectin-3 Human genes 0.000 claims 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims 2
- 102000004257 Potassium Channel Human genes 0.000 claims 2
- 241000251539 Vertebrata <Metazoa> Species 0.000 claims 2
- 241000269370 Xenopus <genus> Species 0.000 claims 2
- 230000001580 bacterial effect Effects 0.000 claims 2
- 230000003542 behavioural effect Effects 0.000 claims 2
- 244000309464 bull Species 0.000 claims 2
- 210000000170 cell membrane Anatomy 0.000 claims 2
- 230000009137 competitive binding Effects 0.000 claims 2
- 238000012217 deletion Methods 0.000 claims 2
- 230000037430 deletion Effects 0.000 claims 2
- 206010012601 diabetes mellitus Diseases 0.000 claims 2
- 238000003745 diagnosis Methods 0.000 claims 2
- 235000021061 dietary behavior Nutrition 0.000 claims 2
- 235000006694 eating habits Nutrition 0.000 claims 2
- 230000004634 feeding behavior Effects 0.000 claims 2
- 239000003550 marker Substances 0.000 claims 2
- 230000008058 pain sensation Effects 0.000 claims 2
- 230000000149 penetrating effect Effects 0.000 claims 2
- 230000001766 physiological effect Effects 0.000 claims 2
- 229910052700 potassium Inorganic materials 0.000 claims 2
- 239000011591 potassium Substances 0.000 claims 2
- 108020001213 potassium channel Proteins 0.000 claims 2
- 230000008569 process Effects 0.000 claims 2
- 238000000746 purification Methods 0.000 claims 2
- 230000002441 reversible effect Effects 0.000 claims 2
- 239000000126 substance Substances 0.000 claims 2
- 238000006467 substitution reaction Methods 0.000 claims 2
- 238000013519 translation Methods 0.000 claims 2
- 210000005253 yeast cell Anatomy 0.000 claims 2
- 108020004491 Antisense DNA Proteins 0.000 claims 1
- 108020005544 Antisense RNA Proteins 0.000 claims 1
- 108090000994 Catalytic RNA Proteins 0.000 claims 1
- 102000053642 Catalytic RNA Human genes 0.000 claims 1
- 102000036364 Cullin Ring E3 Ligases Human genes 0.000 claims 1
- 229940123935 Galanin receptor agonist Drugs 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 206010037211 Psychomotor hyperactivity Diseases 0.000 claims 1
- 241000283984 Rodentia Species 0.000 claims 1
- 230000003213 activating effect Effects 0.000 claims 1
- 238000007792 addition Methods 0.000 claims 1
- 230000001668 ameliorated effect Effects 0.000 claims 1
- 230000000692 anti-sense effect Effects 0.000 claims 1
- 239000003816 antisense DNA Substances 0.000 claims 1
- 239000002299 complementary DNA Substances 0.000 claims 1
- 230000003247 decreasing effect Effects 0.000 claims 1
- 230000029087 digestion Effects 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 230000004064 dysfunction Effects 0.000 claims 1
- 230000002708 enhancing effect Effects 0.000 claims 1
- 238000009472 formulation Methods 0.000 claims 1
- 230000006801 homologous recombination Effects 0.000 claims 1
- 238000002744 homologous recombination Methods 0.000 claims 1
- 102000050963 human GAL Human genes 0.000 claims 1
- 238000009396 hybridization Methods 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 238000003780 insertion Methods 0.000 claims 1
- 230000037431 insertion Effects 0.000 claims 1
- 239000003446 ligand Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 210000003574 melanophore Anatomy 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 210000000287 oocyte Anatomy 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 230000009467 reduction Effects 0.000 claims 1
- 108091008146 restriction endonucleases Proteins 0.000 claims 1
- 108091092562 ribozyme Proteins 0.000 claims 1
- 238000000926 separation method Methods 0.000 claims 1
- 238000013268 sustained release Methods 0.000 claims 1
- 239000012730 sustained-release form Substances 0.000 claims 1
- 241000701447 unidentified baculovirus Species 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2869—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5082—Supracellular entities, e.g. tissue, organisms
- G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/10—Screening for compounds of potential therapeutic value involving cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Organic Chemistry (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Cell Biology (AREA)
- Endocrinology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Physics & Mathematics (AREA)
- Toxicology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US72813996A | 1996-10-09 | 1996-10-09 | |
| US76796496A | 1996-12-17 | 1996-12-17 | |
| US78726197A | 1997-01-24 | 1997-01-24 | |
| US08/900,230 US6329197B2 (en) | 1996-10-09 | 1997-07-23 | DNA encoding galanin GALR3 receptors and uses thereof |
| PCT/US1997/018222 WO1998015570A1 (en) | 1996-10-09 | 1997-10-09 | Dna encoding galanin galr3 receptors and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE956291T1 true DE956291T1 (de) | 2001-05-23 |
Family
ID=27505578
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE0956291T Pending DE956291T1 (de) | 1996-10-09 | 1997-10-09 | Galanin galr3 rezeptor-kodierende dna und anwendungen |
Country Status (8)
| Country | Link |
|---|---|
| US (5) | US6329197B2 (enExample) |
| EP (1) | EP0956291A4 (enExample) |
| JP (1) | JP2002514055A (enExample) |
| AU (1) | AU741041B2 (enExample) |
| CA (1) | CA2248222A1 (enExample) |
| DE (1) | DE956291T1 (enExample) |
| ES (1) | ES2151465T1 (enExample) |
| WO (1) | WO1998015570A1 (enExample) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6329197B2 (en) * | 1996-10-09 | 2001-12-11 | Synaptic Pharmaceutical Corporation | DNA encoding galanin GALR3 receptors and uses thereof |
| US20030119096A1 (en) * | 1997-01-24 | 2003-06-26 | Bard Jonathan A. | Method of treating an abnormality using a GALR3 receptor antagonist |
| US20020137890A1 (en) * | 1997-03-31 | 2002-09-26 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| US6693182B1 (en) * | 1997-08-22 | 2004-02-17 | Schering Corporation | Mammalian galanin receptors |
| CA2326694A1 (en) * | 1997-12-17 | 1999-06-24 | Merck & Co., Inc. | Galanin receptor galr3 and nucleotides encoding same |
| US6395877B1 (en) | 1998-06-30 | 2002-05-28 | Millennium Pharmaceuticals, Inc. | 14273 receptor, a novel G-protein coupled receptor |
| EP1092024A2 (en) | 1998-06-30 | 2001-04-18 | Millennium Pharmaceuticals, Inc. | 14273 receptor, a g-protein coupled receptor |
| US6448005B1 (en) | 1998-06-30 | 2002-09-10 | Millennium Pharmaceuticals, Inc. | 14723 Receptor, a novel G-protein coupled receptor |
| US7534579B2 (en) | 1998-06-30 | 2009-05-19 | Millennium Pharmaceuticals, Inc. | 14273 receptor, a novel G-protein coupled receptor |
| US6221613B1 (en) | 1998-12-31 | 2001-04-24 | Synaptic Pharmaceutical Corporation | DNA encoding a human melanin concentrating hormone receptor (MCH1) and uses thereof |
| ATE342979T1 (de) | 1999-08-03 | 2006-11-15 | Millennium Pharm Inc | 15571, ein neues gpcr-ähnliches molekül der secretin-ähnlichen familie und dessen verwendungen |
| WO2001087930A2 (en) * | 2000-05-18 | 2001-11-22 | Bayer Aktiengesellschaft | Human galanin receptor-like g protein coupled receptor |
| US20040127502A1 (en) * | 2001-01-31 | 2004-07-01 | Synaptic Pharmaceutical Corporation | Use of GAL3 antagonist for treatment of depression |
| US7081470B2 (en) * | 2001-01-31 | 2006-07-25 | H. Lundbeck A/S | Use of GALR3 receptor antagonists for the treatment of depression and/or anxiety and compounds useful in such methods |
| IL157102A0 (en) | 2001-01-31 | 2004-02-08 | Synaptic Pharma Corp | Use of gal3 receptor antagonists for the treatment of depression and/or anxiety and compounds useful in such methods |
| JP2005507654A (ja) * | 2001-08-27 | 2005-03-24 | トゥラリック インコーポレイテッド | 増幅した癌遺伝子およびそれらの癌への関与 |
| AU2003259759A1 (en) * | 2002-08-07 | 2004-02-25 | Synaptic Pharmaceutical Corporation | Gal3 receptor antagonists for the treatment of affective disorders |
| US7642281B2 (en) * | 2002-08-07 | 2010-01-05 | Helicon Therapeutics, Inc. | Indolone compounds useful to treat cognitive impairment |
| US7220775B2 (en) | 2002-08-07 | 2007-05-22 | H. Lundbeck A/S | Compound useful for the treatment of neuropathic pain |
| AU2005299771A1 (en) * | 2004-10-21 | 2006-05-04 | High Point Pharmaceuticals, Llc | Bissulfonamide compounds as agonists of GalR1, compositions, and methods of use |
| EP2636757B1 (en) * | 2008-05-27 | 2016-11-23 | Dako Denmark A/S | Compositions and methods for detection of chromosomal aberrations with novel hybridization buffers |
| US9303287B2 (en) | 2009-02-26 | 2016-04-05 | Dako Denmark A/S | Compositions and methods for RNA hybridization applications |
| US20100284977A1 (en) * | 2009-04-28 | 2010-11-11 | University Of South Carolina | Expression of Anti-Nociceptive Compounds from Endogenously Regulated Promoters |
| EP2647722B1 (en) * | 2010-12-03 | 2016-07-06 | Tsumura & Co. | Daikenchuto bioassay method and quality management method using same |
| WO2013046033A1 (en) | 2011-09-30 | 2013-04-04 | Dako Denmark A/S | Hybridization compositions and methods using formamide |
| EP3252173A1 (en) | 2011-10-21 | 2017-12-06 | Dako Denmark A/S | Hybridization compositions and methods |
| US9879254B2 (en) | 2012-01-18 | 2018-01-30 | The General Hosptial Corporation | Targeting RNAs to microvesicles |
| KR101514440B1 (ko) * | 2013-12-13 | 2015-04-22 | 고려대학교 산학협력단 | 갈라닌 수용체 3형의 리간드로서 스펙신의 용도 |
| CN113512592A (zh) * | 2021-04-23 | 2021-10-19 | 中国科学院深圳先进技术研究院 | 用于检测甘丙肽分泌细胞的引物、探针以及试剂盒 |
| EP4626454A1 (en) * | 2022-11-29 | 2025-10-08 | Neuracle Science Co., Ltd. | Use of galr2 agonists to treat gastrointestinal and/or endocrine disorders |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5462856A (en) | 1990-07-19 | 1995-10-31 | Bunsen Rush Laboratories, Inc. | Methods for identifying chemicals that act as agonists or antagonists for receptors and other proteins involved in signal transduction via pathways that utilize G-proteins |
| US5401629A (en) | 1990-08-07 | 1995-03-28 | The Salk Institute Biotechnology/Industrial Associates, Inc. | Assay methods and compositions useful for measuring the transduction of an intracellular signal |
| JPH06510363A (ja) | 1990-10-29 | 1994-11-17 | ディカルブ プラント ジェネティクス | 磁気性粒子を使用する生物学的材料の単離 |
| WO1992012997A1 (en) | 1991-01-16 | 1992-08-06 | The General Hospital Corporation | Human galanin |
| WO1992015015A1 (en) | 1991-02-25 | 1992-09-03 | Zymogenetic, Inc. | Methods for detecting galanin antagonists |
| WO1992015681A1 (en) | 1991-03-06 | 1992-09-17 | Garvan Institute Of Medical Research | HUMAN GALANIN, cDNA CLONES ENCODING HUMAN GALANIN AND A METHOD OF PRODUCING HUMAN GALANIN |
| US5576296A (en) | 1991-05-15 | 1996-11-19 | Aktiebolaget Astra | Galanin antagonist |
| SE9101472D0 (sv) | 1991-05-15 | 1991-05-15 | Trion Forskning & Utveckling | Galanin antagonist |
| US5436155A (en) | 1991-12-31 | 1995-07-25 | Arch Development Corporation | Isolated DNA encoding a somatostatin receptor |
| US5290808A (en) | 1992-11-06 | 1994-03-01 | Carter-Wallace, Inc. | Method to control the intake of food |
| FR2716205B1 (fr) | 1994-02-17 | 1996-04-12 | Rhone Poulenc Rorer Sa | Récepteur galanine, acides nucléiques, cellules transformées et utilisations. |
| US6399325B1 (en) | 1994-10-13 | 2002-06-04 | Takeda Chemical Industries, Ltd. | DNA encoding a galanin receptor |
| US6562862B1 (en) | 1994-10-20 | 2003-05-13 | Eli Lilly And Company | Methods of inhibiting physiological conditions associated with an excess of neuropeptide Y |
| US6410686B1 (en) | 1996-06-05 | 2002-06-25 | Bayer Corporation | Galanin receptor 2 protein |
| SE9602822D0 (sv) | 1996-07-19 | 1996-07-19 | Astra Pharma Inc | New receptor |
| PT1342410E (pt) | 1996-07-24 | 2010-05-11 | Neurotargets Ltd | Utilização de um agonista de galanina na preparação de um medicamento para melhorar a memória e outras funções cognitivas |
| US6329197B2 (en) | 1996-10-09 | 2001-12-11 | Synaptic Pharmaceutical Corporation | DNA encoding galanin GALR3 receptors and uses thereof |
| CA2326694A1 (en) | 1997-12-17 | 1999-06-24 | Merck & Co., Inc. | Galanin receptor galr3 and nucleotides encoding same |
-
1997
- 1997-07-23 US US08/900,230 patent/US6329197B2/en not_active Expired - Fee Related
- 1997-10-09 JP JP51773898A patent/JP2002514055A/ja not_active Withdrawn
- 1997-10-09 AU AU48125/97A patent/AU741041B2/en not_active Ceased
- 1997-10-09 CA CA002248222A patent/CA2248222A1/en not_active Abandoned
- 1997-10-09 EP EP19970910850 patent/EP0956291A4/en not_active Withdrawn
- 1997-10-09 ES ES97910850T patent/ES2151465T1/es active Pending
- 1997-10-09 DE DE0956291T patent/DE956291T1/de active Pending
- 1997-10-09 WO PCT/US1997/018222 patent/WO1998015570A1/en not_active Ceased
-
1998
- 1998-04-09 US US09/058,333 patent/US6368812B1/en not_active Expired - Fee Related
- 1998-11-25 US US09/199,737 patent/US6287788B1/en not_active Expired - Fee Related
-
2001
- 2001-01-26 US US09/771,287 patent/US20030082641A1/en not_active Abandoned
- 2001-12-03 US US10/007,132 patent/US7022489B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| EP0956291A1 (en) | 1999-11-17 |
| EP0956291A4 (en) | 2002-10-24 |
| WO1998015570A1 (en) | 1998-04-16 |
| AU741041B2 (en) | 2001-11-22 |
| JP2002514055A (ja) | 2002-05-14 |
| ES2151465T1 (es) | 2001-01-01 |
| US6329197B2 (en) | 2001-12-11 |
| US20010009766A1 (en) | 2001-07-26 |
| US20030027254A1 (en) | 2003-02-06 |
| US7022489B2 (en) | 2006-04-04 |
| AU4812597A (en) | 1998-05-05 |
| US6287788B1 (en) | 2001-09-11 |
| US6368812B1 (en) | 2002-04-09 |
| CA2248222A1 (en) | 1998-04-16 |
| US20030082641A1 (en) | 2003-05-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE956291T1 (de) | Galanin galr3 rezeptor-kodierende dna und anwendungen | |
| DE732875T1 (de) | Verfahren zur veränderung des essverhaltens dafür verwendbare verbindungen und dns die einen hypothalamischen atypischen neuropeptid y/peptid yy rezeptor (y5) kodiert | |
| DE802972T1 (de) | Für die rezeptoren des neuropeptids y/peptid yy(y2) kodierende nukleinsäuren und ihre verwendung | |
| DE746332T1 (de) | Dna koheserial für einen rezeptor (y4) aus mensch für neuropeptid y/peptid yy/bauchspeichelabrüsen-polypeptid und seine verwendung | |
| DE530265T1 (de) | Dns, die für menschliche 5-ht 1d rezeptoren kodiert, und verwendungen davon. | |
| DE574579T1 (de) | Dna kodierend für den menschlichen 5-ht if? rezeptor und seine verwendung. | |
| DE69317883T2 (de) | Neue Sieben-Transmembran-Rezeptor V28 | |
| Dineley-Miller et al. | Gene transcripts for the nicotinic acetylcholine receptor subunit, beta4, are distributed in multiple areas of the rat central nervous system | |
| Bunzow et al. | Molecular cloning and tissue distribution of a putative member of the rat opioid receptor gene family that is not a μ, δ or κ opioid receptor type | |
| Hershey et al. | Organization, structure, and expression of the gene encoding the rat substance P receptor | |
| DE819167T1 (de) | Dns codierend für galanin galr2 rezeptoren und deren verwendung | |
| DE69133135T2 (de) | Menschliche neuronale nikotin-acetylcholin-rezeptor-verbindungen und methoden ihres einsatzes | |
| DE69534351T2 (de) | Motorneuronlebenserhaltungsgen: ein Gen für spinale Muskelatrophie | |
| DE69233469T2 (de) | Menschliche Calcium-Kanale und Verwendungen davon | |
| James et al. | Embryonic expression of the period clock gene in the central nervous system of Drosophila melanogaster. | |
| DE585415T1 (de) | Dns-kodierend für den menschlichen 5-ht 1e rezeptor und seine verwendung. | |
| DE69938240T2 (de) | Neuer g-protein-gekoppelter rezeptor | |
| DE624100T1 (de) | Für einen humanen serotoninrezeptor (5-ht4b) kodierende dns und ihre verwendung. | |
| DE60031418T2 (de) | 15571, ein neues gpcr-ähnliches molekül der secretin-ähnlichen familie und dessen verwendungen | |
| DE69633131T2 (de) | Rezeptor des y-y5 neuropeptids | |
| DE60037126T2 (de) | POLYMORPHISMEN DES MENSCHLICHEN HPXR Gens UND IHRE ANWENDUNG IN DIAGNOSE UND THERAPIE | |
| DE60025595T2 (de) | Verfahren zum Diagnostizieren der Suszeptibilität eines Diabetikers für ein erhöhtes Risiko für die Entwicklung von diabetischer Retinopathie | |
| DE69735604T2 (de) | Hypophysentumor verursachende gene und verwandte produkte | |
| DE69427921T2 (de) | Epsilon opioid rezeptor und dessen verwendungen | |
| DE60019433T2 (de) | Ampk-gamma variante, dafür kodierende dna sequenzen, und deren verwendung |